Skip to main content
. 2022 Aug 11;4(12):1015–1023. doi: 10.1016/j.cjco.2022.08.003

Figure 5.

Figure 5

Trend of guideline-directed medical therapy (GDMT) between 2013 and 2018. Black: proportion of patients on triple therapy at any dose each fiscal year (%). Red: proportion of patients on optimum GDMT each fiscal year. Optimum GDMT defined as receiving ≥ 50% of the target dose for angiotensin-converting enzyme inhibitor/angiotensin receptor blocker/angiotensin receptor-neprilysin inhibitor, ≥ 50% of the target dose for beta blocker, and any dose of mineralocorticoid receptor antangonist. CI, confidence interval.